Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Biohaven Ltd. recently reported that its Phase 2 proof-of-concept trial of BHV-7000 for major depressive disorder failed to meet the primary MADRS endpoint over six weeks versus placebo, although the ...

Nevertheless, there is data that the ketogenic diet can be helpful for depression. It is a low-carbohydrate diet that allows ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...

Overall tolerability and safety were observed, with adverse events primarily mild or moderate and resolving spontaneously.

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.

Taking probiotics and magnesium together is considered safe and may help with mood and the gut microbiome. It's not ...